Search

The Kids Research Institute Australia cancer researcher, Dr Jason Waithman, has been named Cancer Council WA’s 2021 Cancer Researcher of the Year.

The Robert Connor Dawes Foundation has joined forces with the Ethan Davies Fellowship to co-fund a The Kids Research Institute Australia initiative aimed at uncovering new treatments for aggressive childhood brain tumours.

This year for Childhood Cancer Awareness Month, we got to know the sarcoma research team at Telethon Kids.

The Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.

The Kids Research Institute Australia researchers may have unlocked a vital key to reducing the progression of leukaemia in children, potentially prompting a change in thinking around the best way to target treatment.

Dr Nick Gottardo, Co-Head of The Kids Research Institute Australia's Brain Tumour Research Team, has been announced a nominee for the 2018 WA Australian of the Year Award

Personalised medicine for childhood cancers in West Australia is a step closer thanks to the Zero Childhood Cancer program’s state clinical trial launched today

The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases (RTKs) consists of EGFR, ErbB2, ErbB3, and ErbB4. These receptors play key roles in cell proliferation, angiogenesis, cell migration, and in some cases, tumor promotion.

Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA‐4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB.

With immune checkpoint therapy (ICT) having reshaped the treatment of many cancers, the next frontier is to identify and develop novel combination therapies to improve efficacy. Previously, we and others identified beneficial immunological effects of the vitamin A derivative tretinoin on anti-tumour immunity.